AP NEWS

Immune Checkpoint Inhibitors Market by Type & Application - Global Opportunity Analysis & Industry Forecast (2018-2025) - ResearchAndMarkets.com

December 17, 2018

DUBLIN--(BUSINESS WIRE)--Dec 17, 2018--The “Immune Checkpoint Inhibitors Market by Type and Application - Global Opportunity Analysis and Industry Forecast, 2018-2025” report has been added to ResearchAndMarkets.com’s offering.

According to the report, the global immune checkpoint inhibitors market was valued at $10,540 million in 2017, and is expected to reach $65,427 million by 2025, growing at a CAGR of 25.6% from 2018 to 2025.

Based on type, the PD-1 inhibitor segment was the major revenue contributor in 2017, and is anticipated to continue this trend during the forecast period, however, PD-L1 inhibitor segment is projected to exhibit the fastest growth.

By application, the lung cancer segment presently dominates the market, and is expected to remain dominant during the forecast period, however, the bladder cancer segment is projected to show fastest growth.

Based on type, the PD-L1 inhibitor segment is expected to experience rapid growth, registering a CAGR of 28.6% from 2018 to 2025.

Depending on application, the lung cancer segment held nearly half of the global market share in 2017, and is expected to remain dominant throughout the forecast period.

Market Dynamics

Drivers

Increase in Incidence of Cancer Across the Globe Surge in Global Geriatric Population Supportive Reimbursement Policies for Immune Checkpoint Inhibitors Surge in Healthcare Expenditure Worldwide

Restraints

Higher Cost of Immune Checkpoint Inhibitors

Opportunities

Increase in Number of Pipeline Drugs Growth Opportunities in the Emerging Markets

Key Players

AstraZeneca PLC Bristol-Myers Squibb Company Eli Lilly and Company (ARMO Biosciences) Fortress Biotech Inc. (Checkpoint Therapeutics Inc.) F. Hoffmann-La Roche Ltd. (Genentech Inc.) Immutep Limited Merck & Co. Inc. Merck KGaA (EMD Serono Inc.) Novartis AG Pfizer Inc.

List of Other Players in the Value Chain

Incyte Corporation NewLink Genetics

Key Topics Covered

Chapter 1: Introduction

Chapter 2: Executive Summary

Chapter 3: Market Overview

Chapter 4: Immune Checkpoint Inhibitors Market, by Type

Chapter 5: Immune Checkpoint Inhibitors Market, by Application

Chapter 6: Immune Checkpoint Inhibitors Market, by Region

Chapter 7: Company Profiles

For more information about this report visit https://www.researchandmarkets.com/research/jft73c/immune_checkpoint?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181217005353/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Oncology Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 12/17/2018 07:38 AM/DISC: 12/17/2018 07:38 AM

http://www.businesswire.com/news/home/20181217005353/en

AP RADIO
Update hourly